Friday, October 29, 2021

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses

 Lexaria Bioscience Corp. (NASDAQ: LEXX) was recently part of coverage by Zacks Small-Cap Research analysts based on its market potential. Zacks, which focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators, valued the company at $15 per share. The valuation was based on the company’s portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption and the multiple potential uses of the technology. The technology is also relatively low-cost, with the capacity to produce up to 400,000 consumer packaged goods through existing manufacturer relationships. A recent article reads, “Zacks notes the potential market reach of Lexaria’s technology if regulatory approved for use in pharmaceuticals, given that hypertension affects about 150 million people nationwide and over a billion worldwide, many of whom find existing medicines less than optimal. The ongoing COVID pandemic has also heightened attention on the need for antivirals to treat ever-present virus infections. And there are about a billion smokers worldwide who could potentially benefit from alternative methods of delivering nicotine to avoid the lung-deleterious effects of inhaling burned or vaporized substances.”

To view the full article, visit https://ibn.fm/7MzaR

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX 

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Flora Growth (FLGC) Receives Global Medical Cannabis Certification, Launches New CBD Brand

 

  • Flora Growth Corp. is an international cannabis consumer packaged goods distributor and cultivator based in Colombia that has built an ecosystem that will support market-leading innovation within categories that matter most to consumers exploring plant-based consumer goods.
  • The company recently obtained the Good Agricultural and Collection Practices (“GACP”) certification from international certification agency and global leader in medical cannabis certification Control Union Medical Cannabis Standard (“CUMCS”)
  • Flora Growth also just announced the launch of a new brand named Munzhi that will initially provide 12 CBD products for wellness, hair, body, and face benefits
  • Flora Growth’s Colombian operations are already producing more than 190 products, 63 of which are INVIMA-registered over-the-counter (“OTC”) products and have received three GMP certifications from the agency regulating Colombia’s food and drug trade

International cannabis brand builder and cultivator Flora Growth Corp. (NASDAQ: FLGC) is preparing to expand its global footprint with the development of a new collection of cannabidiol (CBD) wellness lifestyle products. Flora Growth’s Flora Lab division is launching the new Munzhi brand with 12 products across four categories: Wellness, Hair, Body, and Face. Launch efforts have been initially focused on the Colombian market, though the company will also be selling through an online shop and shipping around the world. 

Colombian President Ivan Duque loosened the country’s limits on cannabis trade in July, permitting the export of dry cannabis flowers used in food, beverage, cosmetics and textiles markets, and delivering Colombian countries confidence that they can leap into Europe’s and North America’s pharmaceutical markets, according to a CNN news report (https://ibn.fm/rilT5). 

Flora Growth has already established a cultivation and processing base in Colombia. The company bought 100 hectares — about 247 acres — in central Colombia and has established production at this base, named Cosechemos, at a cost the company estimates to be around 6 cents per gram of dried cannabis flower, a fraction of the go-to price that ranges from 50 cents to $2 in the United States, according to the news report.

The Munzhi brand combines CBD as an active ingredient with other plant-based ingredients such as lavender oil and chamomile coconut for a facial serum, shampoo, conditioner, shower gel, body ointment and a moisturizing lotion, with plans to expand product offerings over time. 

“Through market studies, consumers have indicated they want the wellness benefits of cannabis, but at an affordable price. Munzhi helps fill that need as well as an important gap in our product portfolio,” Flora Growth President and CEO Luis Merchan stated in a news release about Munzhi (https://ibn.fm/1U1fN). 

Flora Lab recently received its cosmetics GMP certification from Colombia’s food and drug regulatory agency Instituto Nacional de Vigilancia de Medicamentos y Alimentos (“INVIMA”) — its third GMP certification overall — and now serves as Flora Growth’s division for R&D and manufacturing of pharmaceuticals, cosmetics, and nutraceuticals. 

The lab operates a modern, 16,000-square-ft manufacturing facility that produces more than 190 products, 63 of which are INVIMA-registered over-the-counter (“OTC”) products. With the three GMP certifications, Flora Growth can pursue distribution agreements for products that contain CBD as well as non-CBD products in markets where access requires GMP certification (https://ibn.fm/A1Ety). 

The company has more than 2,500 global distribution channels through pharmacies and wholesale clients and aims to continuing expanding them. Neighbor country Panama recently passed legislation legalizing medical cannabis (https://ibn.fm/8JEZt) and Flora Growth’s non-binding LOI with Panamanian importer and distributor Robust Farms Inc. promises to grant Flora a pipeline into that market (https://ibn.fm/MIgdg). 

On Oct. 25, Flora Growth announced it has received the Good Agricultural and Collection Practices (GACP) certification by the Control Union Medical Cannabis Standard (“CUMCS”), a leading international certification agency and global leader in medical cannabis certification. 

“In advance of this milestone, our team has signed several LOI’s for the sale and distribution of dry flower and derivative products to several international jurisdictions, including the EU, Australia, and Latin America,” Flora’s Chief Revenue Officer Jason Warnock stated (https://ibn.fm/Qg5jz). “We are now in the position to unlock the significant potential from Cosechemos as we continue building our global distribution network.”

For more information, visit Flora Growth’s website at https://floragrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Transforming Treatment of Fibromyalgia and Chronic Pain Conditions

 

  • In July, Tryp appointed Dr. Robin Carhart-Harris as the Chairman of its Scientific Advisory Board and Dr. Daniel Clauw, M.D., as a member
  • Commenting on the appointments, Tryp Chairman and CEO Greg McKee expressed his appreciation at the pair’s commitment to the alleviation of chronic pain and other diseases with psychedelic-based therapies as well as the company
  • Fibromyalgia affects millions globally, but existing approved treatments have limited efficacy and/or cause significant side effects
  • Tryp aims to remedy this, alleviating the suffering of millions of patients

In February of 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company, appointed Dr. Robin Carhart-Harris to its Scientific Advisory Board (“SAB”) (https://ibn.fm/jSASb). The founder of the first-of-its-kind Center for Psychedelic Research at Imperial College London and the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco, Dr. Carhart-Harris continues to be instrumental in advising Tryp through the development of its psilocybin programs. 

In July, (https://ibn.fm/NkpfQ), Tryp also appointed Dr. Daniel Clauw, M.D. as a new member of the board. A Professor of anesthesiology, medicine (Rheumatology), and psychiatry at the University of Michigan, Dr. Clauw serves as the Director of the university’s Chronic Pain and Fatigue Research Center. He is also a world-renowned expert on fibromyalgia and nociplastic pain.

“I would like to thank Dr. Robin Carhart-Harris and Dr. Daniel Clauw for their persistent commitment not only to Tryp but also to the alleviation of chronic pain and other diseases with psychedelic-based therapies,” said Tryp Chairman and CEO Greg McKee following the July appointments.

Dr. Clauw’s commitment and work are captured in a 2020 Scientific American article titled “The Unexpected Diversity of Pain” (https://ibn.fm/NNuXh). The article, which discusses three types of pain (nociceptive, neuropathic, and nociplastic), noted that Dr. Clauw is passionate about helping people with nociplastic pain, a kind of long-misunderstood pain that could underpin chronic conditions, including fibromyalgia. 

According to the article, nociplastic pain “results from no obvious inflammation or injury. Rather, it’s as if the volume knob for pain is turned up way too high, not at the pain site itself but further afield.” This type of pain appears to originate in parts of the central nervous system – the brain or spinal cord – that receive, transmit, or process pain signals.

“These nerves misfire, creating a sensation of pain even though nothing may be wrong. The localization of the problem, the central nervous system, is why Clauw prefers to call it ‘central sensitization.’ The classic example is fibromyalgia, which causes pain that seems to stem from muscles, tendons, and joints, despite the real problem lying in the brain or spinal cord,” explained the article. 

According to Tryp’s internal analysis, over 4 million people suffer from fibromyalgia in the United States. Globally, the condition affects an estimated 3-6% of the population (roughly 232-465 million people) (https://ibn.fm/AR0oK). Unfortunately, despite the disease afflicting millions, researchers have not yet made substantial gains in treating fibromyalgia at its origin. Existing FDA approved treatments, for example, have limited efficacy and/or significant side effects. Tryp is looking to change this narrative.

Through the guidance of its SAB, which also includes Joel Castellanos, M.D., Rachel Wervick, Ph.D., Derek Ott, M.D., and William Schmidt, Ph.D., coupled with research-based work conducted in collaboration with the University of Michigan, Tryp hopes to transform the existing treatment of fibromyalgia, along with other forms of chronic pain, and relieve the suffering of millions of patients.

To this end, Tryp recently announced that it expects to file a separate Investigational Drug (“IND”) application before the end of October for its Phase 2a study in fibromyalgia through a collaboration with the University of Michigan (https://ibn.fm/jweV9). 

Having already received IND authorization for a Phase 2a clinical trial in phantom limb pain, Tryp is moving forward with the academic collaboration for this condition. In addition, the company is continuing to advance the partnership for a Phase 2a clinical trial in complex regional pain syndrome. 

Meanwhile, Tryp announced that the FDA had placed a clinical hold on its Phase 2a study for eating disorders, including binge eating disorder and hypothalamic obesity. 

For more information, visit the company’s website at www.TrypTherapeutics.com. 

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF  

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – AmpliTech Group Inc. (NASDAQ: AMPG) to Relocate Headquarters, Expand Manufacturing Capacity

 AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art, signal-processing components for satellite and 5G communications networks, defense, space and other commercial applications, plans to move its manufacturing and headquarters operations into a new 20,000 square-foot facility located in Hauppauge, New York. The company has signed an initial seven-year lease on the property. The company, whose present facility measures 13,100 square feet, observed that the new facility allows AMPG to bring together its design, engineering, and sales and marketing teams together under one roof, a move that will support greater collaboration and operational efficiency; the move, which is slated to be complete by Q1 2022, also provides significant room for growth. “It has been our goal to consolidate our two Long Island locations into a new and enhanced, purpose-driven facility built around our needs,” said AmpliTech Group CEO Fawad Maqbool in the press release. “There, we expect to benefit from an enhanced customer experience, greater collaboration across our business units and improved economies of scale, while also providing an expanded footprint for both internal and external growth. The near-term completion of this effort represents another important step in our vision to expand AmpliTech’s growth potential and capabilities.”

To view the full press release, visit https://ibn.fm/5nWQz

About AmpliTech Group Inc.

AmpliTech designs, develops and manufactures state-of-the-art radio frequency (“RF”) components for global satellite communications, telecom (5G and IoT), space, defense and quantum computing markets as well as systems and component design consulting services. AmpliTech has a 13-plus-year track record of developing high-performance custom solutions to meet the unique needs of some of the largest companies in the global industries that it serves. The company is proud of the unique skills, experience and dedication of its focused team, which enables AMPG to deliver superior solutions, faster time to market, competitive pricing and excellent customer satisfaction and repeat business. For more information about the company, please visit www.AmpliTechInc.com.

NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Makes Strategic Additions to its Leadership; Completes Platinum Vape Management Transition

 

  • RWB appointed Chris Ecken as the new CFO effective October 2021
  • Ecken will lend over 25 years of experience from the alcohol beverage industry, helping RWB to shape sustainable long-term growth
  • RWB also announced Colby De Zen’s appointment to its board of directors
  • He will be integral to RWB’s move to close critical assets in Michigan and expedite expansions in Florida, California, Arizona, Illinois, Massachusetts and Oklahoma
  • RWB also completed Platinum Vape LLC. (“PV”) management transition, with the addition of Shea Alderete, Joaquin Rodriguez and Craig Rosevear to its management
  • RWB plans to bank on growing demand in Michigan and California to scale up production of PV vape carts

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has announced the appointment of two new members to its team: Christopher Ecken and Colby De Zen. Experienced financial executive Chris Ecken becomes the company’s new Chief Financial Officer (“CFO”), while strategic investor and entrepreneur Mr. Colby De Zen becomes the company’s newest board member. The move is being made to strengthen the executive team and its board.

Mr. Ecken brings over 25 years of experience in executive finance at Brown-Forman, an NYSE-listed player in the alcohol beverage industry and a producer of some of the world’s most recognizable alcohol brands, including Jack Daniels(R), Herradura(R) and Woodford Reserve(R) (https://ibn.fm/wP3QF).

“We welcome Chris Ecken as a key addition to the breadth and depth of our management team. His extensive experience as a financial executive will be a tremendous asset,” noted Brad Rogers, the Chief Executive Officer (“CEO”) of RWB.

“His rise through the ranks and track record of accomplishments at each level is testament to his financial acumen, visionary leadership and strategic mindset. We anticipate his specialized skills will help shape sustainable long-term growth, the shift to cannabis industry safe banking, and an upward trajectory toward a listed exchange for Red White & Bloom,” he added.

Throughout his career, Ecken has championed the global revenue management initiative focused on creating sustainable growth. He is also known for his push for the full implementation of international and regional restructuring and leading a cultural mindset shift away from standard budgeting and reporting, instead focusing on continuous planning, actionable business insights, and data-driven analytics.

While confirming his appointment, Ecken noted, “I’m looking forward to leveraging my extensive experience within the spirits industry as I lead Red White & Bloom’s finance organization during this exciting time of growth for the company and the cannabis industry overall.”

Mr. Colby De Zen’s addition to RWB’s board of directors will be effective upon completion of any regulatory or other requirements as applicable (https://ibn.fm/VReeV). As one of the managing directors of De Zen Family Office, a corporation responsible for deploying significant capital in the public and private sectors, RWB is confident that De Zen will lend his vast operational and executive management expertise to the company. This will help with the company’s growth and the achievement of both short-term and long-term goals.

De Zen currently serves as Vice President of Trunkeast Investment, an enterprise with more than 2,000 employees and over $1 billion in annualized revenue. He is responsible for overseeing the day-to-day operations of the company, with a focus on operational efficiency, mergers and acquisitions (“M&A”) activities, as well as cost management.

“I believe that RWB is at an inflection point where substantial shareholder value can be created through continued operational efficiency and execution of RWB’s plans for growth. I am looking forward to working with Brad, and the team, as RWB turns the corner on a number of strategic initiatives,” noted De Zen.

Brad Rogers expressed his enthusiasm for De Zen’s appointment and the strong relationship that RWB has with the De Zen group. He reckoned that the appointment comes at the right time given that the company is preparing to close on critical assets in Michigan while also expediting expansions in Florida, California, Arizona, Illinois, Massachusetts and Oklahoma.

“Their (De Zen Group) strategic involvement and support have been instrumental to Red White & Bloom Brands’ growth. We are excited to have Colby join the team and look forward to working together,” Rogers added.

RWB also announced the completion of an agreement for the transition of the management at its Platinum Vape, LLC (“PV”). RWB also announced having settled all additional PV acquisition purchase price consideration and redeemed a total of $5 million in convertible debentures that were previously convertible at $0.57 per share (https://ibn.fm/Yn2Pm).

This management transition saw the addition of three new faces, including Shea Alderete and Joaquin Rodriguez, both of whom would serve as Co-General Managers of RWB California’s day-to-day operations. In addition, Craig Rosevear would be the new RWB West US Regional Controller.

While making the announcement, Brad Rogers noted, “We know how valuable each and every member of our company is to our continuing success. In this time when so many companies are struggling to attract and retain their staff, we are proud to welcome our new team members, congratulate the existing RWB management team members who have taken on expanded roles, and thank all members of our team for their dedication and hard work as we continue to drive growth of both PV and overall results in each state.”

RWB estimates that in November, production of PV vape carts will increase to over 450,000, a projection that has made expansion of the PV brand a top priority. Michigan and California are proving to be the two vital promising markets pushing for this growth, prompting focus on PV and streamlining its operations.

The agreement between the former PV owners and RWB entailed the former’s resignation as directors and officers from all RWB entities and waiving any further considerations regarding potential earn-out that formed part of the original purchase consideration. This was initially recorded as a $7.5 million liability on the company’s financial statement, $5 million of which was redeemed in convertible debentures at $0.57 per share, coupled with the private purchase of $10 million of convertible debentures.

“Platinum Vape experienced unprecedented growth over the last couple of years, and our acquisition of PV last year was a watershed event for RWB. In addition to the current changes, we expect the further transition for management of the PV segment into a state-specific focus will allow for the expansion of the brand to each state in which RWB operates, while facilitating compliance for the regulatory and marketing nuances that are unique to each jurisdiction,” noted Brad Rogers.

For more information, visit the company’s website at www.RedWhiteBloom.com. 

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php